Trial Profile
A Multicenter Phase II Trial of Pemetrexed Plus Carboplatin With or Without Apatinib in Patients With Advanced Non-small Cell Lung Cancer Without EGFR Mutation, ALK Gene Rearrangement, and ROS1 Gene Rearrangement
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Carboplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms APPEAL
- 26 May 2017 New trial record